[英语新闻]Ent for chronicHBV: Adaptation is not needed for the majority

StephenW

<http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3600274/ZZ680655367925639220014/?news_id=1196&newsdt=051811&subspec_id=481>

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for
the majority of naive patients with a partial virological response

Hepatology, 05/13/2011  Clinical Article

Zoutendijk R et al. – Entecavir(ETV) monotherapy can be continued in
nucleos(t)ide analogue–naive patients with a detectable HBV DNA at week
48, particularly in those with a low viral load at week 48, as long–term
ETV leads to a virological response in the vast majority of patients.

Methods• 333 chronic hepatitis B(CHB) patients treated with entecavir
monotherapy were investigated in a multi- center cohort study .

• Nucleos(t)ide analogue(NA)-naive population consisted of 243 patients,
while 90 were NA-experienced.

Results

• Virological response (VR, HBV DNA <80 IU/mL) was achieved in 48%, 76%
and 90% of HBeAg-positive and in 89%, 98% and 99% of HBeAg-negative
NA-naive patients at week 48, 96 and 144, respectively.

• 36 of 175 (21%) NA-naïve patients with at least 48 weeks follow-up had
a detectable load at week 48 (partial virological response, PVR).

• 29 (81%) patients with PVR reached VR during prolonged ETV monotherapy
and none of them developed ETV-resistance.

• Among 22 patients with HBV DNA <1000 IU/mL at week 48, VR was achieved
in 21 (95%) patients, compared to eight (57%) of 14 patients with HBV DNA
<1000 IU/mL.

• Continuous HBV DNA decline was observed in most patients without VR
during follow-up and in three patients adherence was suboptimal according
to the treating physician.

• ETV was safe and did not affect renal function or cause lactic
acidosis.



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

恩替卡韦治疗慢性乙型肝炎：适应不是必须的
与部分病毒学应答的大多数没有治疗过病人大多数天真

肝脏病，2011年5月13号临床条

Zoutendijk R等。 -恩替卡韦（ETV）单药治疗能继续在
核苷（酸）类似物的IDE-天真与检测乙肝病毒DNA的病人周
48尤其是在低病毒载量在48周者外，作为长期
ETV导致了对绝大多数患者的病毒学应答。

方法•333慢性乙型肝炎（CHB）患者恩替卡韦治疗
单药进行了调查，一个多中心队列研究。

•核苷（酸）类似物的IDE（NA）的，天真的人口由243例患者，
而90名纳经验。

结果

•病毒学应答（虚拟现实，乙肝病毒DNA的“80国际单位/毫升）达到了48％，76％
和90％的HBeAg阳性和89％，98％和99 HBeAg阴性％
在48周，96和144，分别娜天真的病人。

•36175（21％），钠天真的患者至少有48周的后续了
在48周（部分病毒学应答，PVR）的检测负载。

•29（81％），PVR的患者达到单一虚拟现实在长时间的ETV
其中没有

ETV
发展性。

其中22例HBV DNA的患者•<48周1000国际单位/毫升，实现了虚拟现实
21（95％）患者，比八（57％）的患者14例乙型肝炎病毒DNA
<1000国际单位/毫升。

•连续下降乙型肝炎病毒DNA结果表明，大多数患者无虚拟现实
随访期间以及在三个坚持并不理想，根据患者
临床医师决定。

•

ETV
是安全的，不影响肾功能或导致乳酸
酸中毒。